全文获取类型
收费全文 | 1308篇 |
免费 | 90篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 41篇 |
妇产科学 | 11篇 |
基础医学 | 165篇 |
口腔科学 | 18篇 |
临床医学 | 140篇 |
内科学 | 183篇 |
皮肤病学 | 21篇 |
神经病学 | 141篇 |
特种医学 | 201篇 |
外科学 | 99篇 |
综合类 | 45篇 |
预防医学 | 172篇 |
眼科学 | 20篇 |
药学 | 33篇 |
中国医学 | 1篇 |
肿瘤学 | 111篇 |
出版年
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 15篇 |
2020年 | 8篇 |
2019年 | 19篇 |
2018年 | 25篇 |
2017年 | 18篇 |
2016年 | 12篇 |
2015年 | 29篇 |
2014年 | 32篇 |
2013年 | 40篇 |
2012年 | 60篇 |
2011年 | 52篇 |
2010年 | 40篇 |
2009年 | 42篇 |
2008年 | 55篇 |
2007年 | 50篇 |
2006年 | 74篇 |
2005年 | 49篇 |
2004年 | 48篇 |
2003年 | 48篇 |
2002年 | 47篇 |
2001年 | 42篇 |
2000年 | 37篇 |
1999年 | 46篇 |
1998年 | 35篇 |
1997年 | 51篇 |
1996年 | 39篇 |
1995年 | 31篇 |
1994年 | 26篇 |
1993年 | 23篇 |
1992年 | 26篇 |
1991年 | 20篇 |
1990年 | 28篇 |
1989年 | 22篇 |
1988年 | 24篇 |
1987年 | 32篇 |
1986年 | 26篇 |
1985年 | 22篇 |
1984年 | 14篇 |
1983年 | 7篇 |
1982年 | 13篇 |
1981年 | 14篇 |
1980年 | 15篇 |
1979年 | 4篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 6篇 |
1962年 | 2篇 |
排序方式: 共有1404条查询结果,搜索用时 31 毫秒
1.
Alba Tristán-Noguero PhD Eva Borràs PhD Marta Molero-Luis PhD Tessa Wassenberg MD PhD Tessa Peters MSc Marcel M. Verbeek PhD Michel Willemsen MD PhD Thomas Opladen MD PhD Kathrin Jeltsch PhD Roser Pons MD PhD Beat Thony PhD Gabriella Horvath MD Zuhal Yapici MD Jennifer Friedman MD Keith Hyland PhD Guillermo E. Agosta MD Eduardo López-Laso MD Rafael Artuch MD PhD Eduard Sabidó PhD Àngels García-Cazorla MD PhD 《Movement disorders》2021,36(3):690-703
2.
3.
Cerebellar developmental deficits underlie neurodegenerative disorder spinocerebellar ataxia type 23
Cleo J.L.M. Smeets Kai Yu Ma Simon E. Fisher Dineke S. Verbeek 《Brain pathology (Zurich, Switzerland)》2021,31(2):239
Spinocerebellar ataxia type 23 (SCA23) is a late‐onset neurodegenerative disorder characterized by slowly progressive gait and limb ataxia, for which there is no therapy available. It is caused by pathogenic variants in PDYN, which encodes prodynorphin (PDYN). PDYN is processed into the opioid peptides α‐neoendorphin and dynorphins (Dyn) A and B; inhibitory neurotransmitters that function in pain signaling, stress‐induced responses and addiction. Variants causing SCA23 mostly affect Dyn A, leading to loss of secondary structure and increased peptide stability. PDYN R212W mice express human PDYN containing the SCA23 variant p.R212W. These mice show progressive motor deficits from 3 months of age, climbing fiber (CF) deficits from 3 months of age, and Purkinje cell (PC) loss from 12 months of age. A mouse model for SCA1 showed similar CF deficits, and a recent study found additional developmental abnormalities, namely increased GABAergic interneuron connectivity and non‐cell autonomous disruption of PC function. As SCA23 mice show a similar pathology to SCA1 mice in adulthood, we hypothesized that SCA23 may also follow SCA1 pathology during development. Examining PDYN R212W cerebella during development, we uncovered developmental deficits from 2 weeks of age, namely a reduced number of GABAergic synapses on PC soma, possibly leading to the observed delay in early phase CF elimination between 2 and 3 weeks of age. Furthermore, CFs did not reach terminal height, leaving proximal PC dendrites open to be occupied by parallel fibers (PFs). The observed increase in vGlut1 protein—a marker for PF‐PC synapses—indicates that PFs indeed take over CF territory and have increased connectivity with PCs. Additionally, we detected altered expression of several critical Ca2+ channel subunits, potentially contributing to altered Ca2+ transients in PDYN R212W cerebella. These findings indicate that developmental abnormalities contribute to the SCA23 pathology and uncover a developmental role for PDYN in the cerebellum. 相似文献
4.
De Novo Mutations in the Motor Domain of KIF1A Cause Cognitive Impairment,Spastic Paraparesis,Axonal Neuropathy,and Cerebellar Atrophy 下载免费PDF全文
Jae‐Ran Lee Myriam Srour Doyoun Kim Fadi. F. Hamdan So‐Hee Lim Catherine Brunel‐Guitton Jean‐Claude Décarie Elsa Rossignol Grant A. Mitchell Allison Schreiber Rocio Moran Keith Van Haren Randal Richardson Joost Nicolai Karin M.E.J. Oberndorff Justin D. Wagner Kym M. Boycott Elisa Rahikkala Nella Junna Henna Tyynismaa Inge Cuppen Nienke E. Verbeek Connie T.R.M. Stumpel Michel A. Willemsen Sonja A. de Munnik Guy A. Rouleau Eunjoon Kim Erik‐Jan Kamsteeg Tjitske Kleefstra Jacques L. Michaud 《Human mutation》2015,36(1):69-78
KIF1A is a neuron‐specific motor protein that plays important roles in cargo transport along neurites. Recessive mutations in KIF1A were previously described in families with spastic paraparesis or sensory and autonomic neuropathy type‐2. Here, we report 11 heterozygous de novo missense mutations (p.S58L, p.T99M, p.G102D, p.V144F, p.R167C, p.A202P, p.S215R, p.R216P, p.L249Q, p.E253K, and p.R316W) in KIF1A in 14 individuals, including two monozygotic twins. Two mutations (p.T99M and p.E253K) were recurrent, each being found in unrelated cases. All these de novo mutations are located in the motor domain (MD) of KIF1A. Structural modeling revealed that they alter conserved residues that are critical for the structure and function of the MD. Transfection studies suggested that at least five of these mutations affect the transport of the MD along axons. Individuals with de novo mutations in KIF1A display a phenotype characterized by cognitive impairment and variable presence of cerebellar atrophy, spastic paraparesis, optic nerve atrophy, peripheral neuropathy, and epilepsy. Our findings thus indicate that de novo missense mutations in the MD of KIF1A cause a phenotype that overlaps with, while being more severe, than that associated with recessive mutations in the same gene. 相似文献
5.
Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry 下载免费PDF全文
6.
7.
Heng Sheng Sow Hreinn Benonisson Cor Breukel Remco Visser Onno J.H.M. Verhagen Arthur E.H. Bentlage Conny Brouwers Jill W.C. Claassens Margot M. Linssen Marcel Camps Thorbald van Hall Ferry Ossendorp Marieke F. Fransen Gestur Vidarsson J. Sjef Verbeek 《International journal of cancer. Journal international du cancer》2019,144(2):345-354
Immunomodulatory antibodies blocking interactions of coinhibitory receptors to their ligands such as CTLA-4, PD1 and PD-L1 on immune cells have shown impressive therapeutic efficacy in clinical studies. The therapeutic effect of these antibodies is mainly mediated by reactivating antitumor T cell immune responses. Detailed analysis of anti-CTLA4 antibody therapy revealed that an optimal therapeutic efficacy also requires binding to Fc receptors for IgG, FcγR, mediating depletion of intratumoral regulatory T cells. Here, we investigated the role of Fc binding in anti-PD-L1 antibody therapy in the MC38 C57BL/6 and CT26 BALB/c colon adenocarcinoma tumor models. In the MC38 tumor model, all IgG subclasses anti-PD-L1 showed similar therapeutic efficacy when compared to each other in either wild-type mice or in mice deficient for all FcγR. In contrast, in the CT26 tumor model, anti-PD-L1 mIgG2a, the IgG subclass with the highest affinity for activating FcγR, showed stronger therapeutic efficacy than other IgG subclasses. This was associated with a reduction of a myeloid cell subset with high expression of PD-L1 in the tumor microenvironment. This subclass preference for mIgG2a was lost in C57BL/6 × BALB/c F1 mice, indicating that the genetic background of the host may determine the additional clinical benefit of the high affinity antibody subclasses. Based on these data, we conclude that FcγR are not crucial for anti-PD-L1 antibody therapy but might play a role in some tumor models. 相似文献
8.
9.
Jan F.M. Verbeek Chris H. Bangma Charlotte F. Kweldam Theodorus H. van der Kwast Intan P. Kümmerlin Geert J.L.H. van Leenders Monique J. Roobol 《Urologic oncology》2019,37(2):138-144
Introduction
The use of risk calculators predicting clinically significant prostate cancer (csCaP) on biopsy reduces unnecessary biopsies and overdiagnosis of indolent disease compared to a Prostate Specific Antigen (PSA) strategy. Updating these tools using more specific outcome measures and contemporary predictors could potentially lead to further reductions. Our objective was to assess clinical impact of the 4 kallikrein (4K) score, the Rotterdam Prostate Cancer Risk Calculator (RPCRC), and the combination of both for predicting csCaP based on the latest International Society of Urological Pathology grading system and cribriform growth pattern.Materials and methods
Our prospective cohort consisted of 2,872 men from the first screening round in the European Randomized Study of Screening for Prostate Cancer Rotterdam; biopsy indication PSA ≥ 3.0. The predictive performance of the 4Kscore, RPCRC, and the combination of RPCRC with 4Kscore were assessed with area under the receiver operator characteristic curve (AUC) and calibration plots. Decision curve analysis was used to evaluate the reduction of unnecessary biopsy and indolent CaP.Results
The csCaP was present in 242 (8%) men, and indolent CaP in 578 (20%). The 4Kscore and RPCRC had similar high AUCs (0.88 vs. 0.87; P?=?0.41). The 4Kscore-RPCRC combination improved AUC to 0.89 compared to 4Kscore (P < 0.01) and RPCRC (P < 0.01). The RPCRC and 4Kscore reduced the number of Bx with 42 and 44, respectively, per 100 men at risk compared to a ≥PSA 3.0 strategy without increasing missed csCaP. The RPCRC-4Kscore combination resulted in a slight additional net reduction of 3.3 biopsies per 100 men.Conclusions
The RPCRC and 4Kscore had similar reductions of unnecessary biopsies and overdiagnosis of indolent disease. Combination of both models slightly reduced unnecessary biopsies further. Gain in net benefit must, however, be weighed against additional costs and availability of tests. 相似文献10.